Cargando…

Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials

BACKGROUND: Dose-dense chemotherapy is a widely accepted regimen for high-risk breast cancer patients. However, conflicting survival benefits of pure dose-dense chemotherapy have been reported in different randomized controlled trials (RCTs). This meta-analysis aimed to further assess the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Wenqi, Chen, Shizhe, Xu, Faliang, Zeng, Xiaohua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046095/ https://www.ncbi.nlm.nih.gov/pubmed/30007402 http://dx.doi.org/10.1186/s12957-018-1424-4

Ejemplares similares

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
por: Kümmel, S, et al.
Publicado: (2006)

Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Bonilla, Luisa, et al.
Publicado: (2010)

Selection of breast cancer subtypes to improve benefits of intensive dose‑dense chemotherapy: A systematic meta‑analysis
por: Su, Dan, et al.
Publicado: (2023)

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial
por: Moebus, Volker, et al.
Publicado: (2013)

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
por: Puglisi, Fabio, et al.
Publicado: (2021)

Dose-dense adjuvant chemotherapy for primary breast cancer
por: Fornier, Monica, et al.
Publicado: (2005)

Dose-dense chemotherapy for breast cancer: the story so far
por: Hudis, C
Publicado: (2000)

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2017)

Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials
por: Jonker, D J, et al.
Publicado: (2000)

Pneumocystis jirovecii in a patient on dose‐dense chemotherapy for early breast cancer
por: Khoo, Chloe, et al.
Publicado: (2019)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
por: Rashed, Ahmed, et al.
Publicado: (2023)

Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
por: Shi, Tingyan, et al.
Publicado: (2019)

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma
por: Zhu, Chenjing, et al.
Publicado: (2017)

Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
por: Chen, Yan, et al.
Publicado: (2018)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials
por: Wang, Cuiying, et al.
Publicado: (2018)

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy
por: van Rossum, Annelot G.J., et al.
Publicado: (2017)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

Pneumocystis jirovecii Pneumonia in a Patient with Breast Cancer Receiving Neoadjuvant Dose-dense Chemotherapy
por: Watanabe, Hirofumi, et al.
Publicado: (2019)

Pneumocystis jirovecii Pneumonia in Three Patients With Breast Cancer Receiving Neoadjuvant Dose-Dense Chemotherapy
por: Shiiba, Ritsuya, et al.
Publicado: (2022)

Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
por: Khoshroo, Sara, et al.
Publicado: (2021)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer
por: Brain, E, et al.
Publicado: (2011)

Facile and Scalable Preparation of Pure and Dense DNA Origami Solutions**
por: Stahl, Evi, et al.
Publicado: (2014)

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2011)

Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients
por: Ding, Yuqin, et al.
Publicado: (2020)

Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin
por: Yazawa, Hiroyuki, et al.
Publicado: (2017)

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
por: Jacquemier, Jocelyne, et al.
Publicado: (2011)

Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma
por: Maur, Michela, et al.
Publicado: (2015)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer
por: Popovici, Dorel, et al.
Publicado: (2021)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
por: Kümmel, Sherko, et al.
Publicado: (2018)

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.
por: Stål, O., et al.
Publicado: (1994)

Are you dense? The implications and imaging of the dense breast
por: Smilg, Jacqueline S.
Publicado: (2018)

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
por: Reinisch, Mattea, et al.
Publicado: (2023)

A case of squamous cell carcinoma of the breast achieved a pathological complete response after dose-dense AC + dose-dense PTX
por: Araki, Misato, et al.
Publicado: (2023)

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations
por: Cocciolone, Valentina, et al.
Publicado: (2018)

Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer
por: Landman, Yosef, et al.
Publicado: (2019)

Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome
por: Sharma, Parth, et al.
Publicado: (2022)

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
por: Lakhani, S., et al.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_vkb14sm5ln7npe69csrgbelffr